AWK Stock Financial Analysis - Avadel Pharmaceuticals plc (DB) Stock

Overview

Avadel Pharmaceuticals plc is an Ireland-based biopharmaceutical company, primarily engaged in the development and commercialization of proprietary pharmaceutical products. The company specializes in hospital and other therapeutic products within the United States. One of its key projects involves the development of FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of narcolepsy, which is currently under review by the U.S. Food and Drug Administration (FDA). Avadel’s strategy focuses on leveraging its proprietary drug delivery technologies to provide novel formulations that aim to improve patient outcomes and enhance the overall patient experience, addressing both existing and unmet medical needs within the pharmaceutical sector.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Avadel Pharmaceuticals plc as of 30 June 2025 is 221.07 MM.
The operating income for Avadel Pharmaceuticals plc as of 30 June 2025 is -3.24 MM.
The net income for Avadel Pharmaceuticals plc as of 30 June 2025 is -2.92 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	221.07	-3.24	-2.92
2025-03-31	194.45	-19.36	-26.41
2024-12-31	169.12	-42.40	-48.83
2024-09-30	138.16	-64.00	-72.58
2024-06-30	95.15	-93.29	-106.22
2024-03-31	55.14	-135.59	-156.83
2023-12-31	27.96	-137.85	-160.28
2023-09-30	8.51	-136.16	-158.94
2023-06-30	1.50	-118.08	-142.81
2023-03-31		-94.89	-141.82
2022-12-31		-95.22	-137.46
2022-09-30		-95.14	-132.31
2022-06-30		-103.77	-134.17
2022-03-31		-99.36	-90.31
2021-12-31		-85.60	-77.33
2021-09-30	0.00	-76.72	-66.31
2021-06-30	0.00	-65.05	-56.01
2021-03-31	10.09	-47.66	-5.55
2020-12-31	22.33	-36.66	7.03
2020-09-30	33.33	-29.45	15.57
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30	-0.78	-0.77
2024-06-30	-1.16	-1.16
2024-03-31	-1.80	-1.80
2023-12-31	-2.00	-2.00
2023-09-30	-2.17	-2.17
2023-06-30	-2.17	-2.17
2023-03-31	-2.31	-2.31
2022-12-31	-2.29	-2.29
2022-09-30	-2.24	-2.23
2022-06-30	-2.28	-2.28
2022-03-31	-1.54	-1.54
2021-12-31	-1.32	-1.32
2021-09-30	-1.13	-1.13
2021-06-30	-0.96	-1.06
2021-03-31	-0.10	-0.10
2020-12-31	0.13	0.13
2020-09-30	0.33	0.32
2020-06-30	0.43	0.49
2020-03-31	-0.55	-0.55

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Avadel Pharmaceuticals plc as of 30 June 2025 is 5.45 MM.
The cash from investing activities for Avadel Pharmaceuticals plc as of 30 June 2025 is 23.91 MM.
The cash from financing activities for Avadel Pharmaceuticals plc as of 30 June 2025 is 3.73 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	5.45	23.91	3.73
2025-03-31	-25.43	42.71	3.47
2024-12-31	-46.91	51.78	15.97
2024-09-30	-82.81	64.80	-6.02
2024-06-30	-114.14	69.69	23.26
2024-03-31	-127.98	-33.77	114.08
2023-12-31	-128.51	-50.09	135.34
2023-09-30	-115.85	-55.15	163.07
2023-06-30	-84.42	-62.44	143.32
2023-03-31	-66.49	42.51	46.98
2022-12-31	-70.30	79.70	14.54
2022-09-30	-77.44	72.14	7.92
2022-06-30	-91.88	81.91	-2.68
2022-03-31	-87.94	87.99	2.12
2021-12-31	-77.31	56.93	0.26
2021-09-30	-73.93	48.85	0.45
2021-06-30	-62.88	27.26	0.32
2021-03-31	-60.51	-71.76	117.62
2020-12-31	-48.73	-69.72	179.68
2020-09-30	-37.86	-71.79	179.46
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Avadel Pharmaceuticals plc as of 30 June 2025 is -0.17.
The roe for Avadel Pharmaceuticals plc as of 30 June 2025 is -0.04.
The roic for Avadel Pharmaceuticals plc as of 30 June 2025 is -0.23.
The croic for Avadel Pharmaceuticals plc as of 30 June 2025 is 0.18.
The ocroic for Avadel Pharmaceuticals plc as of 30 June 2025 is -0.22.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.17	-0.04	-0.23	0.18	-0.22
2025-03-31	-0.29	-0.34	-0.43	0.18	-0.42
2024-12-31	-0.44	-0.56	-0.64	-0.21	-0.73
2024-09-30	-0.36	-0.66	-0.98	-0.20	-1.06
2024-06-30	-1.11		-1.36	-0.41	-1.11
2024-03-31	-1.21		-1.29	-0.35	-1.04
2023-12-31	-1.09		-0.96	-0.05	-0.70
2023-09-30	-0.90		-0.55	-0.02	-0.33
2023-06-30	-0.90		-0.55	-0.02	-0.33
2023-03-31	-0.64	-2.57	-1.84	0.29	-0.86
2022-12-31	-0.50	-1.34	-1.05	0.02	-0.62
2022-09-30	-0.50	-1.34	-1.05	0.02	-0.62
2022-06-30	-0.47	-1.13	-1.01	-0.10	-0.69
2022-03-31	-0.31	-0.66	-0.45	0.01	-0.44
2021-12-31	-0.25	-0.48	-0.35	-0.09	-0.35
2021-09-30	-0.20	-0.39	-0.27	-0.10	-0.30
2021-06-30	-0.16	-0.31	-0.21	-0.13	-0.24
2021-03-31	-0.03	-0.17	-0.02	-0.05	-0.22
2020-12-31	0.05		0.02	0.21	-0.17
2020-09-30	0.10		0.05	0.23	-0.13
2020-06-30	0.11		0.06	0.27	-0.11
2020-03-31	-0.12		-0.13	0.39	-0.18

Gross Margins

The gross margin for Avadel Pharmaceuticals plc as of 30 June 2025 is 0.90.
The net margin for Avadel Pharmaceuticals plc as of 30 June 2025 is -0.14.
The operating margin for Avadel Pharmaceuticals plc as of 30 June 2025 is -0.10.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.90	-0.14	-0.10
2025-03-31	0.91	-0.29	-0.25
2024-12-31	0.92	-0.53	-0.46
2024-09-30	0.95	-1.12	-1.04
2024-06-30	0.96	-2.84	-2.46
2024-03-31	0.97	-5.73	-4.93
2023-12-31	0.98	-18.68	-16.00
2023-09-30	0.98	-95.46	-78.93
2023-06-30	0.98	-95.46	-78.93
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31	0.67	-0.55	-4.72
2020-12-31	0.74	0.31	-1.64
2020-09-30	0.76	0.47	-0.88
2020-06-30	0.77	0.39	-0.36
2020-03-31	0.79	-0.38	-0.29